Value through Innovation27 July 2016

Clinical Study Results

  • Talsaclidine - Healthy
    Clinical Study Number 506.109
    Study Indication Healthy
    Product Talsaclidine
    Generic Name Talsaclidine
    Lab Code
    Clinical Phase I
    Study Title

    Investigation of metabolism and pharmacokinetics of talsaclidine after administration of single oral and single intravenous dose of 20 mg of [14C]-labelled talsaclidine to 6 healthy subjects.

    Study Document Trial synopsis 506.109 english
  • Talsaclidine - Healthy
    Clinical Study Number 506.111
    Study Indication Healthy
    Product Talsaclidine
    Generic Name Talsaclidine
    Lab Code
    Clinical Phase I
    Study Title

    Phase I Study of WAL 2014 capsules- Single-Dose Study -

    Study Document Trial synopsis 506.111_CO english
  • Talsaclidine - Healthy
    Clinical Study Number 506.112
    Study Indication Healthy
    Product Talsaclidine
    Generic Name Talsaclidine
    Lab Code
    Clinical Phase I
    Study Title

    Phase I Study of WAL 2014 capsules - Multiple Dose Study -

    Study Document Trial synopsis 506.112_CO english
  • Talsaclidine - Healthy
    Clinical Study Number 506.114
    Study Indication Healthy
    Product Talsaclidine
    Generic Name Talsaclidine
    Lab Code
    Clinical Phase I
    Study Title

    Effects on the airway lumen of single oral doses of talsaclidine (12, 24, 48 and 60 mg) in combination with a single oral doses of 160 mg propranolol in comparison to the effects of the monosubstances (60 mg talsaclidine and 160 mg propranolol) in healthy elderly male volunteers (partially randomised, open label, intraindividual comparison)

    Study Document Trial synopsis 506.114 english
  • Talsaclidine - Alzheimer Disease
    Clinical Study Number 506.203
    Study Indication Alzheimer Disease
    Product Talsaclidine
    Generic Name Talsaclidine
    Lab Code
    Clinical Phase IIb
    Study Title

    Efficacy and safety of 6, 12, 24, and 36 mg tid po and 36 mg bid potalsaclidine (free base) for 12 weeks in a double-blind, randomised, placebo-controlled parallel group comparison in patients with mild to moderate dementia of Alzheimer type

    Study Document Trial synopsis 506.203_CO english
  • Talsaclidine - Alzheimer Disease
    Clinical Study Number 506.208
    Study Indication Alzheimer Disease
    Product Talsaclidine
    Generic Name Talsaclidine
    Lab Code
    Clinical Phase IIb/III
    Study Title

    An open-label multicentre, follow-up trial to assess the long-term safety and tolerability of oral administration of talsaclidine 24mg tid in patients with mild to moderate dementia of the Alzheimer type

    Study Document Trial synopsis 506.208 english
  • Talsaclidine - Alzheimer Disease
    Clinical Study Number 506.209
    Study Indication Alzheimer Disease
    Product Talsaclidine
    Generic Name Talsaclidine
    Lab Code
    Clinical Phase IIb
    Study Title

    Efficacy and safety of 48 mg talsaclidine (free base) tid po (Panel1) and 60mg talsaclidine (free base) tid po (Panel2) for 12 weeks in a double­blind, randomised, placebo-controlled within escalating dose panels in 150 patients with mild to moderate dementia of Alzheimer type

    Study Document Trial synopsis 506.209_CO english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.